{"id":"NCT00088452","sponsor":"Children's Hospital Medical Center, Cincinnati","briefTitle":"Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study","officialTitle":"Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-07","primaryCompletion":"2013-01","completion":"2016-08-31","firstPosted":"2004-07-27","resultsPosted":"2020-10-14","lastUpdate":"2020-10-14"},"enrollment":453,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Childhood Absence Epilepsy","Petit Mal Epilepsy","Epilepsy","Seizures"],"interventions":[{"type":"DRUG","name":"Ethosuximide","otherNames":["Zarontin"]},{"type":"DRUG","name":"Lamotrigine","otherNames":["Lamictal"]},{"type":"DRUG","name":"Valproic acid","otherNames":["Depakote"]}],"arms":[{"label":"Ethosuximide","type":"ACTIVE_COMPARATOR"},{"label":"Lamotrigine","type":"ACTIVE_COMPARATOR"},{"label":"Valproic acid","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the best initial treatment for childhood absence epilepsy.","primaryOutcome":{"measure":"Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy","timeFrame":"First 16-20 weeks of double blind therapy","effectByArm":[{"arm":"Ethosuximide","deltaMin":81,"sd":null},{"arm":"Lamotrigine","deltaMin":43,"sd":null},{"arm":"Valproic Acid","deltaMin":85,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"30 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":14,"exclusionCount":10},"locations":{"siteCount":31,"countries":["United States"]},"refs":{"pmids":["23167925","27986874","26311751","20200383","28916534"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":155},"commonTop":["Fatigue","Headache","Hyperactivity","Nausea, vomiting, or both","Hostility"]}}